Christian Buske, MD, is the Medical Director at the Comprehensive Cancer Center and the Institute of Experimental Cancer Research at the University Ulm, Ulm, Germany as well as an Attending Physician and Professor of Medicine at the University Hospital of Ulm, Ulm, Germany.
Prof. Buske obtained his medical degree from the University of Münster, Münster, Germany, qualifying in 1992. In 1997, Prof. Buske completed his residency at the Medical Clinic, University of Göttingen, Göttingen, Germany where he stayed to practice as an Assistant Doctor before moving to Canada to work as a Research Associate at BC Cancer Agency, Vancouver, Canada. In 2003, Prof. Buske became a specialist in internal medicine and completed his specialization in hematology/oncology before becoming a Senior Physician in 2009 at the Großhadern Clinic, Munich, Germany.
Prof. Buske holds membership for various societies such as the European Society for Medical Oncology (ESMO) and American Society of Hematology (ASH). He is also the President of the German Lymphoma Alliance (GLA) and sits on the editorial board of the Leukemia journal.
Speaking on Waldenström’s macroglobulinemia and follicular lymphoma therapeutics
Prof. Buske’s research primarily focuses on novel therapeutic strategies in indolent B-cell non-Hodgkin lymphoma, namely follicular lymphoma and Waldenström’s macroglobulinemia. Prof. Buske is the Principal Investigator for various clinical trials, with his most recent involvement including a Phase III trial investigating the combination of carfilzomib with ibrutinib for Waldenström’s macroglobulinemia (NCT04263480).